<?xml version="1.0" encoding="UTF-8"?>
<p>Influenza vaccines were first licensed for commercial production in 1945 [
 <xref rid="B10-tropicalmed-04-00132" ref-type="bibr">10</xref>]. The propagation in embryonated chicken eggs [
 <xref rid="B11-tropicalmed-04-00132" ref-type="bibr">11</xref>] is still the most prevalent method for production. However, recent developments include an FDA-approved quadrivalent cell-based vaccine grown in the Madin Darby Canine Kidney (MDCK) cell line [
 <xref rid="B12-tropicalmed-04-00132" ref-type="bibr">12</xref>] and a trivalent recombinant influenza vaccine produced from a baculovirus expression vector in the Sf9 armyworm cell line [
 <xref rid="B13-tropicalmed-04-00132" ref-type="bibr">13</xref>]. These cell-based systems can be quickly scaled up for mass-production and circumvent the potential limited supply of eggs during pandemics when poultry availability may also suffer.
</p>
